Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
NKGen Biotech, Inc. - Common Stock
(NQ:
NKGN
)
0.3501
+0.0101 (+2.97%)
Streaming Delayed Price
Updated: 3:56 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about NKGen Biotech, Inc. - Common Stock
NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
October 29, 2024
From
NKGen Biotech
Via
GlobeNewswire
NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024)
October 15, 2024
From
NKGen Biotech
Via
GlobeNewswire
NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
October 08, 2024
From
NKGen Biotech
Via
GlobeNewswire
NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate Alzheimer’s Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial
September 12, 2024
From
NKGen Biotech
Via
GlobeNewswire
NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From
NKGen Biotech
Via
GlobeNewswire
NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report
August 22, 2024
From
NKGen Biotech, Inc.
Via
GlobeNewswire
NKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer’s Association International Conference
July 30, 2024
From
NKGen Biotech
Via
GlobeNewswire
NKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer’s Association International Conference
July 18, 2024
From
NKGen Biotech
Via
GlobeNewswire
NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors
July 15, 2024
From
NKGen Biotech
Via
GlobeNewswire
NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
June 12, 2024
From
NKGen Biotech
Via
GlobeNewswire
Spotlighting Unexplored Stocks in Focus: NKGN, INBS, BTBT, PRSO, MGOL
May 24, 2024
Via
AB Newswire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies
February 07, 2024
Via
Get News
Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies
February 07, 2024
New York, Feb 7, 2024 - (Plato Data) - On Thursday February 2, 2024, the bio industry welcomed the parliament’s passage of a bill that adds regenerative medicine organizations to the list of those...
Via
TheNewswire.com
NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial
December 30, 2023
Via
Get News
NKGen Biotech Advances Alzheimer's Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial
December 29, 2023
SANTA ANA, Calif., Dec. 29, 2023 - (Plato / Amplifi via 500NewsWire) -- NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient...
Via
TheNewswire.com
NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.
October 24, 2023
Via
Get News
Exposures
Product Safety
NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.
October 24, 2023
SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics,...
Via
TheNewswire.com
Exposures
Product Safety
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.